
BREAKING: New Mexico Health Department Proposes Scrapping In-Person Exam, Landlord Sign-Off After Public Outcry
Public response letter following significant pushback also confirms microdosing is allowed in approved settings
Contributor ·

* These figures come from Cherry’s provider case studies, so individual results vary. Details at withcherry.com/provider-reviews. Payment options through Cherry are issued by the following financing partners: withcherry.com/financing-partners
Support Independent Psychedelic Journalism
Want to financially support original, independent reporting like this? You can! Donate at the link below.
NEWS
New Mexico Health Department Proposes Scrapping In-Person Exam, Landlord Sign-Off After Public Outcry
Public response letter following significant pushback also confirms microdosing is allowed in approved settings.
By Jack Gorsline
New Mexico State Capitol
Santa Fe, NM
Source: TourismNM.Com
SANTA FE, N.M. — Following significant pushback from grassroots psychedelic advocates and state lawmakers alike, the New Mexico Department of Health has announced plans to strip two controversial provisions from its proposed medical psilocybin rules: a mandatory in-person checkup with an independent certifying clinician and a requirement for landlord approval at treatment sites. Detailed in a Nov. 9 response to public feedback on draft rule 7.35.3 NMAC, these updates represent proposed amendments rather than finalized regulations.
The state's shift comes in response to what officials described as a "substantial volume of comments," which raised concerns that the initial draft would burden rural residents, military veterans, patients at the end of life, and individuals living in federally assisted housing. Laid out in a 10-page letter from Deputy General Counsel Christopher D. Woodward to rulemaking Hearing Officer Craig Erickson of Utton & Kery, P.A., the proposal also shortens patient enrollment timelines, relaxes group session staffing requirements, and clarifies that microdosing is not prohibited in approved settings. The department also says it does not intend to charge a fee for permits, certificates, or applications.
Under the original text, patients were required to undergo an in-person examination within the previous six months, conducted by a separate certifying clinician holding a New Mexico controlled-substance registration. Commenters argued that this requirement burdened rural patients, raised costs and failed to accommodate patients at the end of life, and that it would create greater obstacles for veterans treated within the Department of Veterans Affairs system, whose providers, as federal employees, are prohibited from certifying patients for psilocybin, a Schedule I drug under federal law.
To address these concerns, health officials plan to eliminate the separate certifying clinician role, the six-month in-person exam requirement, and the controlled-substance registration requirement altogether. Instead, treating practitioners will manage entry into the program by handling patient screening, referrals, and certifications directly. Although the Medical Psilocybin Act (NMSA 1978, Section 26-2D-3(H)) defines a qualified patient as one whose clinician has judged them a medically appropriate candidate, the department noted that practitioners are a type of clinician certified by the department, so practitioner certification meets that statutory requirement.
Under the updated section 8(B), practitioners must attest that they completed a required department screening tool. They must refer the patient to a medical provider if the screening indicates medical risks, if the patient hasn't seen a medical provider in the previous 12 months, or at the practitioner's own discretion. The rule will list contraindicated conditions and treatments including cardiovascular disease, seizure disorder or history of seizure, moderate or greater head trauma, hypertension, history of stroke or cerebrovascular disease, asthma or COPD, diabetes, psychosis or disease with a risk of psychosis (including bipolar disorder), medication interactions such as lithium and serotonergic drugs, a history of suicide attempt or thoughts of harming oneself or others, and the use of medical devices such as insulin pumps and pacemakers. Practitioners must also attest that the benefits of psilocybin likely outweigh its health risks for the patient, and that any identified medical risks can be adequately addressed during treatment or are covered by a written plan. "This will effectively remove the requirement that every examination be in-person. This screening process will be more individual-specific and should be less burdensome for patients in the program," Woodward wrote.
The agency also intends to strike provisions in sections 11(A) and (B) that would have required healing centers and other approved locations to obtain a statement from the landlord or property owner. Under the new draft, applicants need only attest that they own the property or that they are aware of the legal risk concerning the property. Patients, in turn, must attest that they have been informed of psilocybin's legal status as a federal Schedule I drug and the potential consequences of using it, which the department noted may, in some circumstances, include forfeiture of property.
"In adopting these provisions, the Department seeks to ensure that applicants for healing centers and other approved locations, and patients, are enabled to make informed decisions," Woodward stated in the Nov. 9 letter. Department officials noted that dropping the landlord consent requirement means public concerns regarding potential conflicts with Section 8 and other federally assisted housing programs "are effectively resolved".
“Running shos” shouldn’t return zero results. Gladly understands what your shoppers mean, typos and all, and finds the right products.
To streamline access, the department proposes cutting the maximum processing period in section 8(C) from 30 calendar days to 10 business days. The revision replaces references to "applicant" with "patient" and adds text clarifying that this is an enrollment process rather than a more involved application process. "The patient enrollment process is not intended to be an involved process, and does not require the Department to render any clinical decisions regarding individual patients, or to collect detailed clinical records," the letter notes.
Addressing affordability, a central concern since the state funded a Medical Psilocybin Treatment Equity Fund for patients on low incomes, the letter states that the department "does not intend to charge a fee for permits, certificates, or applications," which it says should help alleviate costs for permitted and certified persons and entities. The department added that it cannot fully assess cost and affordability until more is known about what providers will charge, and that it lacks authority to restrict or set practitioner fees. Responding to commenters who sought a separate low-cost microdosing pathway, the department declined to create one but clarified that the existing framework already accommodates low doses. "Microdosing is not prohibited by the existing framework where the practitioner and patient agree to use low doses, provided that administration occurs in the approved settings as required by statute," Woodward explained.
To help reduce treatment costs further, the department proposed updating group administration ratios to allow one practitioner for every nine patients, supported by at least one additional practitioner, facilitator, or qualified student for every three patients, with the practitioner required only to be in the building, within range to be called in for an emergency, rather than in the session room. Individual sessions will require one practitioner plus one additional practitioner or facilitator. However, regulators declined to allow vertical integration of cultivation and administration, citing potential conflicts of interest and arguing that it could raise statewide production costs and the department's oversight burden. "While the Department does not propose to adopt every edit suggested in public comments, the depth and breadth of comments received has resulted in several substantial revisions," Woodward concluded.
"This is what public comment is supposed to do. New Mexicans showed up, wrote in, and kept advocating month after month. I'm proud of my fellow advocates who stayed steady and put themselves out there fighting for a safe, accessible program," said Chris Peskuski, a Marine Corps veteran in Albuquerque, Heroic Hearts Project Ambassador and a peer facilitator on the University of New Mexico’s psilocybin study for PTSD.
Editor’s Note: This is an evolving story. Stay tuned to Psychedelic State(s) of America for exclusive interviews with the New Mexico advocates and lawmakers behind the regulatory design reform process later this week. For background, read PSA's coverage of the program's accelerated launch and the Oct. 2 rulemaking hearing.
Enjoyed this story?
Subscribe to Psychedelic State(s) of America and share this post with someone who should read it.
Tags
You read to the end
Get PSA News & Investigations in your inbox
Free to read. Free to subscribe.
About the author
Jack Gorsline
Contributor
Jack Gorsline is a Washington, D.C.-based investigative reporter covering the politics of drug policy reform - with a focus on psychedelics and cannabis legalization advocacy both in the United States and around the world. Jack’s reporting has been published by the Boston Institute for Nonprofit Journalism (BINJ), Talking Joints Memo, DoubleBlind Magazine, Filter Magazine, Marijuana Moment, Psychedelic Alpha, Lucid News, Cannabis & Tech Today, Reality Sandwich, High Times Magazine, and featured by Psychedelics Today, Ecstatic Integration, and The Mycopreneur Podcast, GBH Radio, The Microdose from UC’s Berkeley Center for the Science of Psychedelics, among others. Jack is also the founder of both Psychedelic State(s) of America and The Psychedelic Writers Guild (PWG) - a new nonprofit sponsored community building-oriented, collaborative media project being created in partnership with a diverse coalition of psychedelic scientists, journalists, medical practitioners, legal professionals, political advocates, and community leaders from around the world. You can find Jack on Twitter @JackGorsline, Instagram @Jack.Gorsline, Linkedin, Substack, Bluesky, and more!




